Doxorubicin HCL

DRUG3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, ImmunityBio, Inc., Epizyme, Inc.

Conditions

Advanced Epithelioid SarcomaAdvanced Soft-tissue SarcomaHodgkin LymphomaTriple Negative Breast Cancer (TNBC)

Phase 1

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

TerminatedNCT04204941

Epizyme, Inc.Advanced Epithelioid Sarcoma, Advanced Soft-tissue Sarcoma

Start: 2019-12-19End: 2024-06-14Updated: 2026-01-07

Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

WithdrawnNCT03554109

ImmunityBio, Inc.Triple Negative Breast Cancer (TNBC)

Start: 2018-09-30End: 2022-02-09Updated: 2025-02-21

Unknown Phase

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active, not recruitingNCT01868451

Memorial Sloan Kettering Cancer CenterHodgkin Lymphoma

Start: 2013-05-31End: 2026-05-31Updated: 2025-07-09

Related Papers

The evolving management of epithelioid sarcoma

European Journal of Cancer Care2021-07-185 citations

Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).

Journal of Clinical Oncology2021-05-204 citations

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

2020-10-06286 citations

A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.

Journal of Clinical Oncology2020-05-206 citations

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Blood2016-07-2576 citations